The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment scenario . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the loss of exclusivity in key markets has introduced considerable volatility. Investors are now facing the impact of lower-cost alt